Gaucher Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Sanofi, Avro Bio, Freeline Therapeutics, CANbridge, Sanofi, Pfizer

Gaucher Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Sanofi, Avro Bio, Freeline Therapeutics, CANbridge, Sanofi, Pfizer
DelveInsight’s “Gaucher Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gaucher Disease, historical and forecasted epidemiology as well as the Gaucher Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Gaucher Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gaucher Disease, historical and forecasted epidemiology as well as the Gaucher Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Gaucher Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gaucher Disease Market Forecast

 

Some of the key facts of the Gaucher Disease Market Report: 

  • The Gaucher Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to Zimran et al. (2022), estimations for GD type undefined or overall prevalence ranged from 0.11 to 139.0/100,000 people, with North America having the greatest prevalence rates (GD1: 0.26-0.63; GD2 and GD3: 0.02- 0.08)
  • According to Hughes & Sidransky (2023), type 1 GD (GD1) is the most common form in the US, Europe, and affects Ashkenazi Jews more frequently than other populations. All ethnic types experience Type 2 GD (GD2). According to a gene frequency research, there were about 20,000 cases of GD in the United States in the middle of the 1990s. The standardised birth incidence of GD in the general population was estimated by a later survey to be between 0.4 and 5.8 per 100,000, with a prevalence of 0.7 to 1.8 per 100,000
  • An genetic metabolic condition is known as Gaucher Disease (GD). NORD estimates that there are around 6,000 people in the US who have GD. It is inherited from parents to offspring and is brought on by a GBA gene issue
  • Key Gaucher Disease Companies: Sanofi, Avro Bio, Freeline Therapeutics, CANbridge, Sanofi, Pfizer, ISU Abxis Co., Ltd., Shire, Actelion, Amicus Therapeutics, Quintiles, Inc., and others
  • Key Gaucher Disease Therapies: Venglustat, AVR-RD-02, FLT201, CAN103, venglustat (GZ402671), Elelyso, ISU302, VPRIV, Miglustat, afegostat tartrate, velaglucerase, and others
  • The Gaucher Disease epidemiology based on gender analyzed that females born with GD does not have any family history whereas male child born with GD have family history
  • The Gaucher Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gaucher Disease pipeline products will significantly revolutionize the Gaucher Disease market dynamics.

 

Gaucher Disease Overview

A metabolic condition known as Gaucher Disease (GD) is brought on by a lack of the enzyme glucocerebrosidase (GCase). It is the second most prevalent kind of lysosomal storage disorder (LSD) and is classified as such.

 

Get a Free sample for the Gaucher Disease Market Report 

https://www.delveinsight.com/report-store/gauchers-disease-market

 

Gaucher Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gaucher Disease Epidemiology Segmentation:

The Gaucher Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Gaucher Disease
  • Prevalent Cases of Gaucher Disease by severity
  • Gender-specific Prevalence of Gaucher Disease
  • Diagnosed Cases of Episodic and Chronic Gaucher Disease

 

Download the report to understand which factors are driving Gaucher Disease epidemiology trends @ Gaucher Disease Epidemiology Forecast

 

Gaucher Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gaucher Disease market or expected to get launched during the study period. The analysis covers Gaucher Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gaucher Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gaucher Disease Therapies and Key Companies

  • Venglustat: Sanofi
  • AVR-RD-02: Avro Bio
  • FLT201: Freeline Therapeutics
  • CAN103: CANbridge
  • venglustat (GZ402671): Sanofi
  • Elelyso: Pfizer
  • ISU302: ISU Abxis Co., Ltd.
  • VPRIV: Shire
  • Miglustat: Actelion
  • afegostat tartrate: Amicus Therapeutics
  • velaglucerase: Quintiles, Inc.

 

Discover more about therapies set to grab major Gaucher Disease market share @ Gaucher Disease Treatment Market

 

Gaucher Disease Market Strengths

  • Increasing awareness of Gaucher disease
  • Advances in the understanding of Gaucher disease pathogenesis
  • Pipeline consists of late and early stage candidates.

 

Gaucher Disease Market Opportunities

  • Uptake of potential emerging therapies with better clinical profile expected to be medium-fast due to the present unmet needs.
  • Several organizations are actively working to provide information and increase awareness of such disorders.

 

Scope of the Gaucher Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Gaucher Disease Companies: Sanofi, Avro Bio, Freeline Therapeutics, CANbridge, Sanofi, Pfizer, ISU Abxis Co., Ltd., Shire, Actelion, Amicus Therapeutics, Quintiles, Inc., and others
  • Key Gaucher Disease Therapies: Venglustat, AVR-RD-02, FLT201, CAN103, venglustat (GZ402671), Elelyso, ISU302, VPRIV, Miglustat, afegostat tartrate, velaglucerase, and others
  • Gaucher Disease Therapeutic Assessment: Gaucher Disease current marketed and Gaucher Disease emerging therapies
  • Gaucher Disease Market Dynamics: Gaucher Disease market drivers and Gaucher Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Gaucher Disease Unmet Needs, KOL’s views, Analyst’s views, Gaucher Disease Market Access and Reimbursement 

 

To know more about Gaucher Disease companies working in the treatment market, visit @ Gaucher Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Gaucher Disease Market Report Introduction

2. Executive Summary for Gaucher Disease

3. SWOT analysis of Gaucher Disease

4. Gaucher Disease Patient Share (%) Overview at a Glance

5. Gaucher Disease Market Overview at a Glance

6. Gaucher Disease Disease Background and Overview

7. Gaucher Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Gaucher Disease 

9. Gaucher Disease Current Treatment and Medical Practices

10. Gaucher Disease Unmet Needs

11. Gaucher Disease Emerging Therapies

12. Gaucher Disease Market Outlook

13. Country-Wise Gaucher Disease Market Analysis (2019–2032)

14. Gaucher Disease Market Access and Reimbursement of Therapies

15. Gaucher Disease Market Drivers

16. Gaucher Disease Market Barriers

17.  Gaucher Disease Appendix

18. Gaucher Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services


Posted

in

by

Tags: